Citius Oncology: new institutional accounts ordering LYMPHIR up 78% QoQ

Citius Pharmaceuticals, Inc.

New institutions ordering LYMPHIR increased 78% in Q2 2026 vs. prior quarter; total vial orders up 31%.
LYMPHIR now available in 42 institutions including academic and NCCN centers.
Near-universal payer coverage achieved; initial CTCL market exceeds $400 million.
Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.
Wholesaler reorders have begun reflecting increased institutional demand; revenue recognized on filled wholesale orders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.